Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04765137 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)
A Phase 2 study of Mild Cognitive Impairment, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04765137: Recruiting Phase 2 study of Mild Cognitive Impairment, sponsored by Johns Hopkins University.
NCT04765137 is a Phase 2 study of Mild Cognitive Impairment that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 20 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04765137, a Phase 2 study of Mild Cognitive Impairment, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.
Primary Outcome
MRI based CVR is a newer technique that measures dilatory function of the microvessels which have been shown to be superior to measurement of Cerebral blood flow (CBF) and have also been shown to be low in participants with MCI.
Conditions Studied
Interventions
- DRUG Atorvastatin Oral Tablet
Study Locations (1)
Maryland
- Johns Hopkins University, Bayview Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT04765137 shows while recruiting
NCT04765137 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin Oral Tablet is the first listed.
NCT04765137 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04765137 about?
NCT04765137 is a clinical study titled "Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)". The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.
What is the current status of trial NCT04765137?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-05-21. Estimated completion is 2026-12-31.
What conditions does trial NCT04765137 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
What interventions are being tested in trial NCT04765137?
The interventions under investigation include: Atorvastatin Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04765137?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04765137 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04765137's enrollment target sits among peer trials
20 174th of 205 higher than 24 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study
RECRUITING · Phase 2
-
Rapamycin - Effects on Alzheimer's and Cognitive Health
RECRUITING · Phase 2
-
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
RECRUITING · Phase 2
-
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
RECRUITING · Phase 2
-
Senicapoc in Alzheimer's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI